Pulmonary metastasectomy in patients with renal cell carcinoma: a single-institution experience
Tóm tắt
Pulmonary metastasectomy in patients with renal cell carcinoma (RCC) remains controversial. The purpose of our analysis was to explore the outcome of patients with RCC who underwent pulmonary metastasectomy at our institution. We reviewed data on 25 patients who underwent resection of lung metastasis from 1998 to 2008 at our institution. All patients were treated by radical nephrectomy for primary RCC. Progression-free survival (PFS) ranged from 0.3 to 198.8 months (median 7.4 months), and overall survival (OS) ranged from 2.4 to 198.8 months (median 33.9 months). The 5-year PFS rate was 24.9%, and the OS rate was 35.5%. Although differences in the resectability of the metastasectomy and OS were not significant in univariate or multivariate analyses, the relationship between PFS and the radicality of pulmonary metastasectomy was significant in both the univariate and multivariate analyses (P = 0.004, 0.012, respectively). The results of pulmonary metastasectomy for patients with RCC at our institution indicate that pulmonary metastasectomy should be performed only when the pulmonary metastasis can be completely resected. Additional studies are therefore necessary to evaluate the prognostic factors and to determine the selection criteria for pulmonary metastasectomy in the new era of molecular-targeted agents.
Tài liệu tham khảo
Henriksson C, Haraldsson G, Aldenborg F et al (1992) Skeletal metastases in 102 patients evaluated before surgery for renal cell carcinoma. Scand J Urol Nephrol 26:363–366
Giuliani L, Giberti C, Martorana G et al (1990) Radical extensive surgery for renal cell carcinoma: long-term results and prognostic factors. J Urol 143:468–474
de Kernion JB, Ramming KP, Smith RB (1978) The natural history of metastatic renal cell carcinoma: a computer analysis. J Urol 120:48
Cohen HT, McGovern FJ (2005) Renal-cell carcinoma. N Engl J Med 353:2477–2490
Bellmunt J, Montagut C, Albiol et al (2007) Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents. BJU Int 99:274–280
Lane BR, Rini Bi, Novick AC et al (2007) Targeted molecular therapy for renal cell carcinoma. Urology 69:3–10
Akaza H, Tsukamoto T, Murai M et al (2007) Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn J Clin Oncol 37:755–762
Barney JD, Churchill EJ (1939) Adenocarcinoma of the kidney with metastases to the lung. J Urol 42:269–276
van der Poel HG, Roukema JA, Horenblas S et al (1999) Metastasectomy in renal cell carcinoma: a multicenter retrospective analysis. Eur Urol 35:197–203
Hofmann HS, Neef H, Krohe K et al (2005) Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma. Eur Urol 48:77–82
Assouad J, Petkova B, Berna P et al (2007) Renal cell carcinoma lung metastases: pathologic findings and prognostic factors. Ann Thorac Surg 84:1114–1120
Chen F, Fujinaga T, Shoji T et al (2008) Pulmonary resection for metastasis from renal cell carcinoma. Interact Cardiovasc Thorac Surg 7:825–828
Kanazaki R, Higashiyama M, Fujiwara A et al (2011) Long-term results of surgical resection for pulmonary metastasis from renal cell carcinoma: a 25-year single-institution experience. Eur J Cardiothorac Surg 39:167–172
Guinan P, Sobin LH, Algaba F et al (1997) TNM staging of renal cell carcinoma: Workgroup No. 3. Cancer 80:992–993
Staehler MD, Kruse J, Haseke N et al (2010) Liver resection for metastatic disease prolongs survival in renal cell carcinoma: 12-year results from a retrospective comparative analysis. World J Urol 28:543–547
Reddy S, Wolfgang CL (2009) The role of surgery in the management of isolated metastases to the pancreas. Lancet Oncol 10:287–293
Fujioka T, Obara W, Miki T et al (2009) Evidence-based clinical practice guidelines for renal cell carcinoma (Summary—JUA 2007). Int J Urol 16:339–353
Assouad J, Banu E, Brian E et al (2008) Strategies and outcomes in pulmonary and extrapulmonary metastases from renal cell cancer. Eur J Cardiothorac Surg 33:794–798
Loehe F, Kobinger S, Hatz RA et al (2001) Value of systematic mediastinal lymph node dissection during pulmonary metastasectomy. Ann Thorac Surg 72:225
Cerfolio RJ, Allen MS, Deschamps C et al (1994) Pulmonary resection of metastatic renal cell carcinoma. Ann Thorac Surg 57:339–344
Friedel G, Hurtgen M, Penzenstadler M et al (1999) Resection of pulmonary metastases from renal cell carcinoma. Anticancer Res 19:1593–1596
Plitz S, Meimarakis G, Wichmann MW et al (2002) Long-term results after pulmonary resection of renal cell carcinoma metastases. Ann Thorac Surg 73:1082–1087
Pfannschmidt J, Hoffmann H, Muley T et al (2002) Prognostic factors for survival after pulmonary resection of metastatic renal cell carcinoma. Ann Thorac Surg 74:1653–1657
Sherry RM, Pass HI, Rosenberg SA et al (1992) Surgical resection of metastatic renal cell carcinoma and melanoma after response to interlerukin-2-based immunotherapy. Cancer 69:1850–1855
Kim B, Louie AC (1992) Surgical resection following interleukin 2 therapy for metastatic renal cell carcinoma prolongs remission. Arch Surg 127:1343–1349
Naito S, Yamamoto N, Takayama T et al (2010) Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients. Eur Urol 57:317–326
Motzer RJ, Basch E (2007) Targeted drugs of metastatic renal cell carcinoma. Lancet 370:2071–2073